<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340908</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-SGLT2i</org_study_id>
    <nct_id>NCT04340908</nct_id>
  </id_info>
  <brief_title>Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery</brief_title>
  <official_title>Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hongchang Guo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diabetes have poorer cardiac surgery outcomes compared with non-diabetics.
      Proper blood glucose management is critical to reduce the morbidity and mortality for
      diabetic patients after cardiac surgery.

      SGLT2 inhibitors including dapagliflozin as a new diabetes drug can reduce heart failure
      hospitalization rates and overall cardiovascular mortality in patients with cardiovascular
      disease.

      This study is to assess the impact of one year of treatment of SGLT2 inhibitors on cardiac
      function, postoperative complications and long-term cardiovascular mortality in diabetic
      patients undergoing cardiac surgery.

      The investigators use echocardiography to evaluated cardiac function in diabetic patients
      during perioperative cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mean EF% between the treatment and control study arms</measure>
    <time_frame>2 year</time_frame>
    <description>Echocardiography is used to assess cardiac function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in NTproBNP between the treatment and control study arms</measure>
    <time_frame>2 year</time_frame>
    <description>NT-proBNP is used to assess cardiac function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause postoperative mortality</measure>
    <time_frame>2 year</time_frame>
    <description>All-cause mortality identified during two years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for cardiovascular causes</measure>
    <time_frame>2 year</time_frame>
    <description>Rehospitalization due to cardiovascular diseases during two years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious postoperative infection</measure>
    <time_frame>2 year</time_frame>
    <description>Including postoperative sternal dehiscence, external genital infections, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute postoperative kidney injury</measure>
    <time_frame>2 year</time_frame>
    <description>Acute postoperative kidney injury requiring renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>2 year</time_frame>
    <description>Identified using ICD9 and ICD10 codes and reported as rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>2 year</time_frame>
    <description>Days from date of surgery to hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic ketoacidosis</measure>
    <time_frame>2 year</time_frame>
    <description>Identified using ICD9 and ICD10 codes and reported as rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactic acidosis</measure>
    <time_frame>2 year</time_frame>
    <description>Identified using ICD9 and ICD10 codes and reported as rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative atrial fibrillation</measure>
    <time_frame>7 days</time_frame>
    <description>In this study, postoperative AF was defined as occurrence of the arrhythmia within the first 7 days after cardiac surgery. AF was considered to be present when an irregular rhythm was detected in the absence of P waves and/or an f wave was detected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>10 mg tablet, oral, once daily, 1-year treatment, postoperation</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>matching placebo tablet, oral, once daily, 1-year treatment, postoperation</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old at index date.

          2. Diagnosis of Type 2 Diabetes.

          3. Scheduled for cardiac surgery (coronary artery bypass grafting, valve replacement,
             ventricular assist device, cardiac transplantation, or any other surgery requiring
             thoracotomy).

          4. eGFR ≥ 60 ml/min/1.73 m2.

          5. Patients who agree to receive treatment with SGLT2 inhibitors.

          6. Patients must be on current stable hemodynamic profile , without dehydration.

        Exclusion Criteria:

          1. Diagnosis of Type 1 Diabetes.

          2. eGFR &lt; 60 ml/min/1.73 m2.

          3. Unstable or rapidly progressive renal disease.

          4. Hypersensitivity to dapagliflozin or any excipients.

          5. Severe hepatic disease.

          6. Patients who have participated in any other clinical trial of an investigational
             medicinal product within the previous 30 days.

          7. Any other reason considered by a study physician to be inappropriate for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lai, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei, M.D.</last_name>
    <phone>+86 19800367660</phone>
    <email>weizhipeng@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Mediacal University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei, M.D.</last_name>
      <email>weizhipeng@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Hongchang Guo</investigator_full_name>
    <investigator_title>Attending doctor</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Outcome</keyword>
  <keyword>SGLT2 inhibitors</keyword>
  <keyword>Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

